UPDATE - UBS Initiates Coverage on Intermune (ITMN) with a Neutral; Overshot to Downside, But Stuck Until More Clarity
Tweet
Share
E-mailGet Alerts ITMN Hot Sheet
Price: $73.89 --0%
Rating Summary:
8 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
8 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
UPDATE - UBS initiates coverage on Intermune (Nasdaq: ITMN) with a Neutral rating. PT $13.50.
Analyst, Matthew Harrison, said, "We like InterMune’s focus on orphan drugs as these markets generally yield high prices, data exclusivity and motivated patients. However, the continued uncertainty over EU pricing keeps us on the sidelines. We believe Esbriet, InterMune’s product for Idiopathic Pulmonary Fibrosis (IPF), can be a $500M drug even with an additional 15% price cut, but greater cuts would represent potential downside to our estimates."
To see more ratings on ITMN, Click Here
Analyst, Matthew Harrison, said, "We like InterMune’s focus on orphan drugs as these markets generally yield high prices, data exclusivity and motivated patients. However, the continued uncertainty over EU pricing keeps us on the sidelines. We believe Esbriet, InterMune’s product for Idiopathic Pulmonary Fibrosis (IPF), can be a $500M drug even with an additional 15% price cut, but greater cuts would represent potential downside to our estimates."
To see more ratings on ITMN, Click Here
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DA Davidson Starts Everus (ECG) at Buy
- DA Davidson Starts Comfort Systems USA (FIX) at Buy
- TD Cowen Assumes Sana Biotechnology (SANA) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
